Aquestive Therapeutics Statistics
Total Valuation
AQST has a market cap or net worth of $778.38 million. The enterprise value is $690.69 million.
Important Dates
The last earnings date was Wednesday, November 5, 2025, after market close.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
AQST has 122.00 million shares outstanding. The number of shares has increased by 22.87% in one year.
| Current Share Class | 122.00M |
| Shares Outstanding | 122.00M |
| Shares Change (YoY) | +22.87% |
| Shares Change (QoQ) | +11.33% |
| Owned by Insiders (%) | 3.96% |
| Owned by Institutions (%) | 51.89% |
| Float | 110.92M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 14.58 |
| Forward PS | 13.40 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 15.92 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.93
| Current Ratio | 5.93 |
| Quick Ratio | 5.51 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.27 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -25.50% |
| Return on Invested Capital (ROIC) | -242.86% |
| Return on Capital Employed (ROCE) | -40.43% |
| Revenue Per Employee | $305,613 |
| Profits Per Employee | -$485,768 |
| Employee Count | 142 |
| Asset Turnover | 0.32 |
| Inventory Turnover | 2.31 |
Taxes
| Income Tax | -14,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +48.03% in the last 52 weeks. The beta is 1.58, so AQST's price volatility has been higher than the market average.
| Beta (5Y) | 1.58 |
| 52-Week Price Change | +48.03% |
| 50-Day Moving Average | 6.25 |
| 200-Day Moving Average | 4.14 |
| Relative Strength Index (RSI) | 56.50 |
| Average Volume (20 Days) | 2,694,210 |
Short Selling Information
The latest short interest is 19.20 million, so 15.73% of the outstanding shares have been sold short.
| Short Interest | 19.20M |
| Short Previous Month | 14.74M |
| Short % of Shares Out | 15.73% |
| Short % of Float | 17.31% |
| Short Ratio (days to cover) | 6.28 |
Income Statement
In the last 12 months, AQST had revenue of $43.40 million and -$68.98 million in losses. Loss per share was -$0.70.
| Revenue | 43.40M |
| Gross Profit | 26.16M |
| Operating Income | -55.79M |
| Pretax Income | -68.99M |
| Net Income | -68.98M |
| EBITDA | -55.20M |
| EBIT | -55.79M |
| Loss Per Share | -$0.70 |
Full Income StatementBalance Sheet
The company has $129.06 million in cash and $41.38 million in debt, giving a net cash position of $87.69 million or $0.72 per share.
| Cash & Cash Equivalents | 129.06M |
| Total Debt | 41.38M |
| Net Cash | 87.69M |
| Net Cash Per Share | $0.72 |
| Equity (Book Value) | -4.11M |
| Book Value Per Share | -0.03 |
| Working Capital | 126.10M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$50.45 million and capital expenditures -$492,000, giving a free cash flow of -$50.94 million.
| Operating Cash Flow | -50.45M |
| Capital Expenditures | -492,000 |
| Free Cash Flow | -50.94M |
| FCF Per Share | -$0.42 |
Full Cash Flow StatementMargins
Gross margin is 60.28%, with operating and profit margins of -128.56% and -158.95%.
| Gross Margin | 60.28% |
| Operating Margin | -128.56% |
| Pretax Margin | -158.98% |
| Profit Margin | -158.95% |
| EBITDA Margin | -127.20% |
| EBIT Margin | -128.56% |
| FCF Margin | n/a |
Dividends & Yields
AQST does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -22.87% |
| Shareholder Yield | -22.87% |
| Earnings Yield | -8.86% |
| FCF Yield | -6.54% |
Analyst Forecast
The average price target for AQST is $10.00, which is 56.74% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.00 |
| Price Target Difference | 56.74% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 36.31% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AQST has an Altman Z-Score of -2.17 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.17 |
| Piotroski F-Score | 2 |